Medicenna to Present at Interleukin-2 Therapy Conference

TORONTO and HOUSTON, Aug. 27, 2024 -- Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy firm focused on pioneering Superkines, has announced that it will present two abstracts in oral sessions at the Promise of Interleukin-2 Therapy Conference. This event will be held at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024. 

Medicenna will unveil initial preclinical data on its MDNA209 platform. This platform emphasizes long-acting, high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, which show therapeutic promise for treating autoimmune and graft-versus-host diseases. Additionally, new preclinical data on MDNA113, a first-in-class IL-13Rα2 tumor-targeted and tumor-activated bifunctional anti-PD1-IL-2 Superkine, will be presented.

The scheduled oral presentations are as follows:
- Title: MDNA209, a High Affinity IL-2β Biased IL-2/IL-15 Super-antagonist, for the Treatment of Autoimmune Diseases
Presenter: Dr. Hardeep Kataria
Session Title: Novel IL-2s, Vectorization and Combination Therapies
Session Date and Time: Friday, September 6, 2024; 2 PM CEST (8 AM EST)

- Title: MDNA113, an IL-13Rα2 Tumor Targeting and Conditionally Activatable anti-PD1-IL-2SK BiSKIT Shows Enhanced Safety and Potent Therapeutic Efficacy
Presenter: Dr. Minh To
Session Title: IL-2 in Cancer Therapy
Session Date and Time: Saturday, September 7, 2024; 9 AM CEST (3 AM EST)

Medicenna Therapeutics is dedicated to developing innovative, highly selective IL-2, IL-4, and IL-13 Superkines, as well as pioneering Empowered Superkines. The company's next-generation, long-acting IL-2 Superkine, MDNA11, displays superior affinity for CD122 (IL-2 receptor beta) and lacks CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-fighting effector T cells and NK cells.

Bizaxofusp (formerly MDNA55), Medicenna's IL-4 Empowered Superkine, has been examined in five clinical trials involving over 130 patients. This includes a Phase 2b trial for recurrent GBM, the most prevalent and fatal form of brain cancer. Bizaxofusp has received FastTrack and Orphan Drug status from both the FDA and FDA/EMA.

The company’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, originating from its MDNA209 platform, are being explored as potential treatments for autoimmune and graft-versus-host diseases. Medicenna's early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs aim to enhance Superkines' effectiveness against immunologically “cold” tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!